The currently used standards for human chorionic gonadotropin (hCG) and its ␣ and ␤ subunits (hCG␣ and hCG␤) contain substantial amounts of contaminating variants of hCG and other impurities. Furthermore, some partially degraded forms of hCG and its subunits have become of potential clinical importance, e.g., "nicked" forms of hCG (hCGn) and hCG␤ (hCG␤n), which contain cuts in the peptide backbone between amino acids 44 -45 or 47-48 in hCG␤, and a fragment of hCG␤ (hCG␤cf) consisting of amino acids 6 -40 and 55-92 bound together by disulfide bridges. The IFCC appointed a working group with the aim of preparing new standards for hCG and related substances to improve standardization of their immunoassays. Methods: Large amounts of hCG and its subunits as well as of hCGn, hCG␤n, and hCG␤cf were prepared by previously developed purification methods in combination with hydrophobic interaction chromatography and reversed-phase HPLC. Each preparation was characterized on the basis of amino acid and sequence analyses,
the 3rd International Standard (IS) for hCG (coded 75/ 537) and the 1st IRPs for its dissociated subunits, hCG␣ (75/569) and hCG␤ (75/551) (2, 3 ) . The recently established 4th IS (75/589) was prepared at the same time as the 3rd IS from the same batch and is essentially identical to the 3rd IS, differing only by two separate filling procedures (3 ) .
In addition to preparing improved replacements for the existing standards, the WG undertook preparation of three new standards for urinary metabolites of hCG, namely the ␤-core fragment of hCG␤ (hCG␤cf) and nicked forms of hCG (hCGn) and hCG␤ (hCG␤n). These hCG metabolites, which are found mainly in urine but may also occur in serum (4 -7 ) , are of interest both because of their variable reactivity in existing assays and their potential clinical utility, particularly in urine assays (1, 5, 8 -10 ) . Substantial amounts of these metabolites, as well as traces of protease activity, have been shown to be present in the current standard preparations for hCG (IS 75/537 and 75/589), hCG␣ (IRP 75/569), and hCG␤ (IRP 75/551) (3, 11, 12 ) , and these contaminants may be partly responsible for variability in the behavior of the 3rd/4th IS in various commercial hCG assay systems (13, 14 ) . Contamination with hCGn is also a major problem because some hCG assays recognize hCGn poorly, whereas others recognize hCGn and hCG equally, potentially giving rise to calibration errors. Recent advances in purification technologies provided an opportunity to prepare standards essentially devoid of these contaminants (10, 15, 16 ) . The structural characteristics of the various forms of hCG that were to be prepared, together with their approved IFCC nomenclature, are shown in Fig. 1 .
This report describes the preparation and chemical characterization of the new Reference Reagents (RRs) for immunoassay standardization of hCG and hCG-related variants. Detailed data on the purification procedure and protein characterization, HPLC analyses, mass spectra, and amino acid analyses appear in a data supplement available with the online version of this article (http:// www.clinchem.org/content/vol49/issue1/). A description of small-scale purification of hCG and related molecules has appeared earlier (16 ) , as has a progress report on the project (17 ) . Evaluation of the final ampouled standards, including stability studies, value assignment, and comparisons of immunoassay results, will be the subject of separate reports.
Materials and Methods starting material
Two lots (nos. 00010187 and 00006040) of pharmaceutical grade hCG from Diosynth (Division of Akzo/Nobel) with a biological activity of 4200 IU/mg of dry weight were used as starting material for preparation of the standards.
antibodies for western blots
Monoclonal antibodies (mAbs; IDC) with selected specificities were chosen for Western blots: INN(sbruck)-hCG-22 (recognizes hCG and hCG␤-variants; broad specificity; epitope ␤ 2 , located on the top of ␤-strand loops 1 and 3 of hCG␤; amino acid regions hCG␤20 -25 and hCG␤68 -77); INN-hFSH-100 (hCG and hCG␣; broad specificity; epitope ␣ 2 on ␤-strand loop 1 of hCG␣; amino acid region hCG␣13-22), INN-hCG-80 (hCG␣-specific; no recognition of dimer; epitope ␣ 6 in the region of the subunit interaction site, amino acids hCG␣33-42), and ISOBM-313, directed against amino acids hCG␤141-144 (epitope ␤ 8 ) (13, 18 -20 ) .
analytical procedures
The methods for amino acid analysis, amino acid sequence analysis, and RP-HPLC were described previously (16 ) . Carbohydrate analyses were performed by the NIHfunded Research Center for Biomedical Complex Carbohydrates (Athens, GA). Monosaccharide composition was analyzed by gas chromatography-mass spectrometry on a HP 5890 gas chromatograph equipped with a Supelco DB1 fused-silica capillary column and interfaced to a 5970 mass spectrum detector. Trimethylsilyl derivatives of the methyl glycosides were prepared from 80 g of each sample by methanolysis in 1 mol/L HCl in methanol at 80°C (18 -22 h), followed by re-N-acetylation with pyridine and acetic anhydride (for detection of amino sugars). The hCG reference preparations described in this report are as follows: hCG is the intact heterodimeric hormone derived from late first trimester pregnancy urine. It consists of hCG␣ and hCG␤ with no peptide bond cleavages in either subunit. hCGn consists of intact hCG␣ combined with hCG␤n, which has peptide bond cleavages in loop 2, generally between amino acid residues 47 and 48 but occasionally between residues 44 and 45 and at other positions. hCG␤ is produced by dissociation of purified hCG and further purified by HPLC to remove nicked and oxidized material. hCG␤n is a nicked form of hCG␤ derived from hCGn; it is sometimes found free in urine specimens. hCG␤cf is composed of hCG␤6 -40 disulfide-bridged (S-S) to hCG␤55-92. hCG␣ is produced by dissociation of purified hCG and further purified by HPLC to remove nicked and oxidized material (not shown).
The samples were then treated with Tri-Sil (Pierce Chemical) sodium dodecyl sulfate-polyacrylamide gel electrophoresis, isoelectric focusing, and western blotting
The purity and composition of the various preparations were assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting (13, 21 ) . Briefly, proteins were loaded on precast polyacrylamide gradient gels (4 -20%; Novex) at equimolar concentrations and separated by SDS-PAGE (Mighty Small II; Hoefer Scientific Instruments) at 200 V for 50 min under nonreducing conditions. For isoelectric focusing (IEF), dry acrylamide gels (6% T) were reswollen to their original thickness in 3% ampholyte solution (Ampholine 3.5-9.5; Amersham Biosciences) with or without the addition of 9 mol/L urea. Protein solutions were diluted with 1 g/L bovine serum albumin in distilled water, and 5-L aliquots were loaded (300 V, 5 mA, 5 W for 30 min) and separated (3000 V, 5 mA, 5 W for 120 min) at 20°C.
Proteins were electrophoretically transferred from SDS-PAGE (3. (13, 18, 20 ) . After extensive washing with phosphate-buffered saline, membranes were incubated for 1 h with goat anti-mouse IgG-horseradish peroxidase (Immunopure; Pierce) diluted 1:1000 in 10 g/L milk powder in phosphate-buffered saline (0.15 mol/L NaCl, 20 mmol/L sodium phosphate, pH 7.4). Chemiluminescent substrate conversion (Super Signal West Dura; Pierce) was detected with Hyperfilm ECL (Amersham International).
time-resolved immunofluorometric assays
The coating, blocking, and incubation steps of the immunofluorometric assays (IFMAs) for hCG, hCG␤, hCG␤cf, and hCG␣ were performed as described for human follicle-stimulating hormone (hFSH) (23 ) . The characteristics of the mAbs against hCG, hCG␤, hCG␤cf, hCG␣, and hFSH have been described (13, 18 ) . These mAbs (IDC) served as RRs in the international TD-7 Workshop on antibodies to hCG and hCG-related molecules (13 ) . The coating mAbs were coded INN(sbruck)-45 (hCGϩhCGn assay), -68 (hCG␤ assay), -106 (hCG␤cf assay), and INNhCG-72 (hCG␣ assay). The detection mAbs (INN-hFSH-158 for the hCG␣-assay; INN-hCG-22, a pan-␤ mAb), for all four other assays (18 ) were labeled with isothiocyanatophenylene triaminotetraacetic acid-europium (Wallac) according to the manufacturer's recommendations. Hormone standards (hCG 3rd IS 75/537, hCG␤ 1st IRP 75/551, hCG␣ 1st IRP 75/569) used to determine the sensitivities and specificities of the IFMAs for hCG, hCG␤, and hCG␣ were kindly provided by the National Institute for Biological Standards and Control. hCG␤cf was a gift by Drs. Klaus Mann and Rudy Hoermann (University of Essen, Essen, Germany).
Inter-and intraassay CVs for each IFMA were Ͻ10% over the entire assay ranges (18 ) . The new RRs were diluted in 0.01 mol/L NaHCO 3 containing 1 g/L bovine serum albumin, aliquoted, snap-frozen in liquid nitrogen, and stored at Ϫ80°C until assayed.
summary of purification protocols
Flow charts for the purification procedures are shown in Fig. 2 (hCG, hCGn, and hCG␤cf) and Fig. 3 (hCG␣, hCG␤, 
biological activity
The biological activities of the hCG preparations were estimated in vivo in male rats by the seminal vesicle weight method (24 ) and in vitro by the Leydig cell method with testosterone production as the endpoint (25, 26 ) . The 3rd IS (75/537) was used as a standard. The in vivo assays were performed in two laboratories and the in vitro determinations in one.
Results purification of hCG, hCGn, and hCG␤cf Purification was started with molecular size fractionation to separate hCG␤cf from the hCG components present in the starting material. Somewhat unexpectedly, the starting lot of Diosynth hCG contained only ϳ10% as much hCG␤cf as that in lots of 10 or 20 years earlier. The method developed in 1972 and used to produce the 3rd IS [CR119; Canfield-Ross preparations of hCG made of Columbia University (CR)-quality hCG] (2 ) was improved by use of modern chromatographic media and the addition of hydrophobic interaction chromatography (Fig. 2) . This permitted separation of hCGn and other minor contaminants from hCG. Some free fragments of hCG␤CTP (␤117-145 and other similar fragments) were also separated by this step. It is not clear whether these peptides had not been removed by previous steps or whether they were introduced by cleavage by some contaminating protease. After gel filtration, hCG␤cf was further purified with use of Blue Sepharose and RP-HPLC.
purification of subunits
Subunit purification was accomplished starting with the CR-quality hCG preparation (Fig. 3) . Although RP-HPLC can dissociate and separate subunits in a single step, oxidized forms and metabolites cause cross-contamination. Thus, oxidized forms of hCG␤ coeluted with hCG␣ and oxidized forms of hCG␣ with hCG␤n. Consequently, the subunits were first separated by anion-exchange chromatography (2 ) and were further purified by RP-HPLC in 0.2 mL/L trifluoroacetic acid. The fractions were immediately brought to a higher pH, lyophilized, incubated to permit recombination with any complementary subunit, and gel-filtered to remove any reformed hCG as well as to reduce salt content. Exposure to low pH was minimized to reduce loss of sialic acid residues.
hCG␤n was prepared directly from the RP-HPLC purification step used to prepare hCG␤. An adequate quantity of hCG␤n was isolated as a byproduct of the purification of hCG␤. A small quantity of urinary ribonuclease remained in the hCG␤n preparation and was not easily removed. Other investigators have also reported copurification of this protein with hCG␤cf (27 ) .
characterization of the preparations
The purity of each preparation was assessed by SDS-PAGE under reducing conditions (Fig. 4) , immunoblotting (Figs. 5 and 6), IFMAs (Table 1) , and by N-terminal sequence analysis ( Table 2 ). The protein content of each preparation was quantified by amino acid analysis [ Table  S1 in the online data supplement (http://www.clinchem. org/content/vol49/issue1/)]. Comparison of the known The five hCG/hCG␤ variants were analyzed with use of mAbs against two different epitopes on free and assembled hCG␤. It should be emphasized that the results of this approach were not quantitative in nature. Although equimolar concentrations of hCG␤ and hCG␤n were loaded in each lane, the same mAb (INN-hCG-22; ␤ 2 ) stained the latter preparation much more intensely. hCG, hCG␤, hCG␤n, and hCG␤cf appeared to be highly pure. The nature of additional bands became obvious when we compared the results of the mAb directed against the hCG␤CTP (epitope ␤ 8 ) with that recognizing an epitope in the core region of hCG␤ (epitope ␤ 2 ): These minute amounts of cross-contaminating molecules in hCG and hCG␤n (-CTPhCG, -CTPhCGn, and -CTPhCG␤/␤n; arrows) lack the end of hCG␤CTP. hCGn obviously contains more of these contaminants, but again hCG␤n might be overestimated, as mentioned above. hCG␣ was constantly negative with both anti-␤ mAbs; thus no significant hCG/hCG␤-associated contamination could be detected (data not shown).
primary structure with the calculated amino acid content showed good agreement.
SDS-PAGE (Fig. 4) confirmed the expected band patterns of purified hCG␣, hCG␤, and hCG as well as the two bands expected for hCG␤cf. Analyses of hCGn by RP-HPLC indicated the presence of ϳ10 -15% of nonnicked hCG.
N-Terminal sequence analyses indicated that each preparation contained Ͻ2-3% contaminants; the limit of detection of the method ( Table 2 ). The single exception As shown previously (21 ) , because the carbohydrate antennae of assembled and nonassembled hCG␤(n) contained many more terminal sialic acids, all preparations except for hCG␤cf and hCG␣ were highly acidic in nature. An array of at least six major bands appeared around pI 4.5. hCG␣ consisted of variants with neutral pI. hCG␤cf was highly basic (pI Ͼ9.5), lacking terminal sialic acids on the carbohydrate units of the core region and the hyperglycosylated hCG␤CTP. Thus, most of it has eluted from the gel. On overexposure of the film, only a contaminating acidic band can be seen, which disappears under dissociating conditions. Interestingly, some hCG variants are resistant to dissociation by urea. The y axis represents the approximate pH values in the gels.
was the hCG␤n preparation, which was contaminated with some urinary ribonuclease (27 ) as described above.
Characterization of the preparations by IEF and subsequent Western blotting (Figs. 5 and 6) with pan anti-␣-subunit and pan anti-␤-subunit antibodies showed that hCG␣ consists of three major bands with an approximately neutral pI. The various forms of hCG-and hCG␤-derived variants displayed at least six major bands around a pI of 4.5. hCGn and hCG␤n appear to be more acidic than hCG and hCG␤. hCG␤cf, with a pI Ͼ9.5, could not be analyzed by this approach. When hCG and hCGn were analyzed by IEF in 9 mol/L urea, the expected subunit patterns were observed (Fig. 6) .
The specific absorbance values for the preparations of hCG and its subunits differed slightly from published values, which were also based on protein content determined by amino acid analysis (Table 3) (2, 16, 28 ) . The extinction values for the 3rd IS were determined by absorbance at 280 nm, whereas for the current preparation, 276 nm was used, possibly contributing to this difference. However, the greater purity of the new preparation could also be responsible for the observed difference.
Results of carbohydrate analysis, RP-HPLC profiles, and mass spectra of the preparations are given in the online data supplement. The mean molecular weights were as follows: hCG, 37 500; hCG␤, 23 500; hCG␣, 14 000; and hCG␤cf, 10 500. Carbohydrate composition [ Table S2 in the online data supplement (http://www.clinchem. org/content/vol49/issue1/)] agreed reasonably well with the expected content of each of the sugars. The sialic acid content (mol/mol) and the expected ranges were as follows: 9.8 (12-16) for hCG; 2.0 (2-4) for hCG␣; 13.3 (8 -12) for hCG␤; 8.5 (12-16) for hCGn, and 8.8 (8 -12) for hCG␤n. The reason for the higher than expected sialic acid content for hCG␤ is not known and may be an experimental artifact. Complete compositional carbohydrate analysis was not performed for CR119 hCG, the 3rd IS, but the sialic acid content of CR119 hCG (10.6% by weight) was very similar to that of the new preparation (11.1% by weight). The percentage of carbohydrate by 
biological activity
The median in vivo biopotency (with the 95% confidence intervals) measured by one laboratory was 15 400 (14 200 -16 800) IU/mg, whereas in the other laboratory, it was 10 300 (8360 -12 600) IU/mg. This laboratory also determined the in vitro biological potency to be 14 100 IU/mg (12 500 -16 000).
properties of the new 1st rr for immunoassay of hCG
The improved overall properties of the new hCG preparation 99/688 are compared with those of the 3rd/4th IS in Table 4 . The free subunits were also improved to the same extent in terms of peptide bond intactness and freedom from contaminants, as described in the analysis above.
Discussion
The major goal of this project was to develop new RRs for hCG and its subunits and major urinary metabolites to facilitate improved standardization and characterization of immunoassays for these analytes. Another goal of the WG was to evaluate the feasibility of assigning values to the standards in substance concentrations (mol/L) rather than in arbitrary units or units based on biological activity. These goals have been achieved: new RRs of high purity have been prepared and assigned values based on amino acid composition. Value assignment of the final RRs issued by WHO will be reported separately. Preparation of the new RRs was achieved by use of an initial purification scheme similar to that for preparation of the 3rd IS of hCG, but more modern chromatographic media provided better separation, although care was taken to retain the microheterogeneity of hCG and its subunits, as revealed by IEF. This microheterogeneity primarily reflects the differences in sialic acid content typical of all glycoprotein hormones, and retention of these natural variants in the final preparations appears desirable. Removal of contaminating forms of hCG and other proteins was achieved by addition of hydrophobic interaction chromatography and RP-HPLC to the purification scheme. Use of hydrophobic interaction chromatography also facilitated removal of any residual traces of protease activities, such as those present in the 3rd IS (3, 12, 29 ) as well as in hCGn and hCG␤cf (15, 16 ) .
Preparation of subunits of superior quality to the last subunit standards, IRP 75/569 and IRP 75/551, was difficult. Direct use of RP-HPLC to separate subunits in a single step was not feasible because oxidized subunits coeluted with the other subunit or with the metabolites. Methionine residues are easily oxidized, and when the single methionine in the hCG␤ subunit is oxidized, hCG␤ coelutes with hCG␣. Because hCG␣ contains three methionines, it may elute as four different peaks. Anionexchange chromatography in urea buffer did not separate oxidized from nonoxidized subunits but did allow good separation of each of the subunits. RP-HPLC was used subsequently to remove oxidized forms from each subunit. Further removal of any complementary subunit was achieved by allowing subunit recombination followed by gel filtration.
Our procedures relied heavily on analytical screening of every column fraction by RP-HPLC to decide which fraction should become part of the pool at each step. The large-scale procedure adopted facilitated production of the large quantity of protein required for IRPs. The preparations were thoroughly characterized with respect to protein and carbohydrate content and the presence of immunoreactive cross-contaminants. Amino acid sequence analysis was essential to verify polypeptide chain integrity and the extent of peptide bond cleavages in nicked materials. Because the sensitivity of Edman sequence analysis for detection of contaminating proteins is ϳ3%, highly sensitive IFMAs and SDS-gel electrophoresis Significant: hCGn, some hCG␤ ϩ hCG␤cf (see Table 1 )
No significant contaminants
Protease activity Present Negligible in conjunction with Western blotting were used for more sensitive assessment of purity. Compared with the 3rd/4th IS for hCG, the new 1st RR for hCG contains much less hCGn, hCG␤, hCG␣, and hCG␤cf (Table 1) . Estimation of the content of contaminating forms of hCG by time-resolved IFMAs showed that the preparations of hCG, hCG␤, hCG␤, and hCG␣ were of excellent purity. Only hCGn contained substantial amounts (Ͼ1%) of hCG, (-CTP)hCG␤(n), and hCG␣ (Table 1 and Figs. 4 and 5) . These results were confirmed by Western blotting (Fig. 6) . No hCG-related contaminants were observed in hCG␤, hCG␤cf, and hCG␣. There are minute amounts of (a) -CTPhCG (hCG lacking the Cterminal portion of hCG␤) and hCG␣ in hCG 99/688, (b) -CTPhCG␤(n) in hCG␤n, and (c) -CTPhCG and -CTPhCG␤(n) and hCG␣ in hCGn. Presumably, a somewhat larger amount of hCG␤/␤n can be found in hCGn. Because the mAbs used for Western blotting recognize the various forms of hCG/hCG␤ with different affinities, the method is not quantitative. Nevertheless, it provides a qualitative screen for those hCG-derived variants for which no purified preparations are available, i.e., hCG and hCG␤ variants truncated at their COOH terminus (-CTPhCG, -CTPhCGn, -CTPhCG␤, and -CTPhCG␤n).
The combination of all these methods facilitated accurate characterization of the preparations and demonstration of their very high quality. Two metabolite preparations were somewhat contaminated: hCGn contained ϳ10% hCG, whereas hCG␤n contained ϳ10% urinary ribonuclease and was the only preparation with detectable foreign protein. This does not prohibit their use for characterization of the specificity of immunoassays for hCG and its subunits.
The sialic acid content of the new reference preparation of hCG is similar to that of CR 119 (the 3rd IS). The major change in protein content observed by N-terminal sequence analysis was complete removal of the peptide bond cleavages within the ␤-subunit at positions 44 -45 and 47-48 (9 ) . This, together with the IEF patterns observed (Fig. 6 ) and the excellent in vivo and in vitro biological activity demonstrated, provides assurance that the hydrophobic step selected molecular species representative of the physiologically relevant active hormone.
The availability of the new reference preparations provides a sound scientific basis for improving the standardization of assays for hCG-related molecules. The 3rd IS for hCG (75/537) was calibrated by bioassay in international units (IU) against the 2nd IS. The subunits, which lack bioactivity, were assigned arbitrary units (also IU) based on mass. This common unitage falsely suggests that such "standardization" of hCG and its subunits has a common basis. Value assignment on the basis of biological activity is appropriate for hCG standards intended for therapeutic purposes. In contrast, for hCG standards used to calibrate immunoassays, value assignment in substance concentrations on the basis of amino acid analysis, as for the RRs reported here, is much more informative. As an important first step toward improving the comparability of immunoassays for hCG, the new standards will allow manufacturers to calculate the cross-reactivity of these six hCG-related molecules in the immunoassays they supply. Inclusion of such data in assay inserts will enable direct comparison of the relative recognition of these molecules in different assay systems. This should be achievable for currently available hCG immunoassays.
Realistically, the new standards are likely to be used for primary calibration of the next generation of hCG immunoassays rather than for current assays. Careful consideration will then be required as to how best to transfer values for the primary (nonnicked) hCG standard to the "working" secondary standards used by manufacturers, because the latter are likely to contain substantial amounts of nicked hCG. At the same time, convincing clinical colleagues of the advantages of adopting molar units for hCG will present a major challenge to laboratorians.
The use of molar units is particularly helpful when the ratios of various forms of hCG are compared, as in the diagnosis of Down syndrome and trophoblastic tumors. Some groups already report results for hCG, its subunits, and fragments in molar concentrations based either on locally prepared standards or on theoretical values calculated from the WHO standards (30, 31 ) . Value assignment in substance concentrations also increases the probability that subsequent standards can be calibrated identically. [Unfortunately this is not possible retrospectively for the 3rd/4th IS because these preparations contain carrier protein.] Measurement of the molar content of protein by amino acid analysis also eliminates some of the practical problems associated with glycoproteins, e.g., difficulties in gravimetric determination of glycoprotein mass because of tight binding of water molecules. Although carbohydrate residues present on glycoproteins rarely affect immunoreactivity, they may strongly affect biological activity, e.g., by modulating the half-lives of circulating glycoproteins or by influencing receptor binding and activation. Because antibodies almost exclusively recognize peptide epitopes, the molar content of proteins, rather than their bioactivity, may be expected to best reflect what is measured by immunoassays.
Although antibodies that recognize glycan-associated epitopes within hCG are very rare (32 ) , the potential utility of measurement of hyperglycosylated hCG (acid variants of hCG with high carbohydrate content) in early pregnancy and in cancer patients has been the subject of recent reports (33 34 ) . The current interest in hyperglycosylated hCG is related to the hCG isoforms recognized by antibody B152, which is directed to the glycans and peptide structure within the hCG␤ COOH-terminal peptide (CTP) region (35 ) , but this antibody does not recognize all forms of hyperglycosylated hCG., e.g., those with modifications in the N-glycan region only. Preparation of a reference standard for hyperglycosylated hCG would be desirable but was not part of the focus of the current project.
It is not likely, however, that the presence of various hyperglycosylated hCG forms in serum or urine causes errors in current commercial assays for hCG. It has recently been shown by IEF, Western blotting, and sandwich immunoassays that all mAbs tested, including those against all major epitopes located in the immunodominant regions such as the top of the two adjacent ␤-strand loops 1 and 3 of hCG␤, recognize the entire spectrum of glycosylation variants, including deglycosylated hCG, asialo-hCG, variants of more neutral pI, and highly acidic (hyperglycosylated) variants of pregnancy hCG as well as highly purified acidic hCG variants of tumor patients (21 ) . All of these epitopes are therefore predominantly determined by the protein backbone, and the carbohydrate moieties that form a biochemical basis for hCG heterogeneity are neither of major antigenic relevance nor are they structurally related to any immunodominant antigenic region. Most manufacturers of "hCG" reagent sets use mAbs with epitope specificities identical to the reference mAbs used for these studies (13 ) . The calibration of the RRs in substance concentrations (mol/L) is undoubtedly an important advantage for the measurement of hCG that is heterogeneous in nature with respect to glycosylation.
In conclusion, we have produced highly purified preparations of hCG, hCG␣, hCG␤, and three partially degraded forms of these. The protein contents of these preparations were determined by amino acid analysis. The WHO has approved these preparations as RRs, and their use should facilitate improved comparability among immunoassays for measurements of hCG, its subunits, and its metabolites. The characterization of the final WHO preparations as well as their application in external quality assessment (proficiency testing) schemes will be reported separately.
